TickerFacts.

Q/C Technologies, Inc. (QCLS): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.75M
Year ended 2025-12-31
2016-12-31: $207.1K2017-12-31: $41.7K2025-12-31: $1.75M$1.75M
2016-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.75Mn/a2026-04-15, From 2025-01-01
No annual figure between 2017-12-31 and 2025-12-31.
2017-12-31$41.7K-79.9%2018-07-13, From 2017-01-01
2016-12-31$207.1Kn/a2018-07-13, From 2016-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Q/C Technologies, Inc. (QCLS)2025-12-31$1.75Mn/a
Achieve Life Sciences, Inc. (ACHV)2025-12-31$3.0Kn/a
Immucell Corp (ICCC)2025-12-31$1.25M+168.5%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$3.19M+517.2%
Alpha Teknova, Inc. (TKNO)2025-12-31$1.15M+2.0%
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31$187.3K-12.8%
Volitionrx Ltd (VNRX)2025-12-31$89.6K-67.7%
Aspira Women's Health Inc. (AWHL)2025-12-31$16.0K-56.8%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$2.71M+41.4%

Compare QCLS, ACHV, ICCC, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗